Akanda

Akanda FCF Margin

The Free Cash Flow Margin of Akanda (AKAN) as of Oct 25, 2026 is -3,085.58 %. In the previous year, Free Cash Flow Margin was -726.52 % — a change of 324.71% (lower).

FCF Margin

-3,085.58 %

YoY

324.71%

Last updated:

Free Cash Flow Margin of Akanda is 2025 -3,085.58 % . Free Cash Flow Margin of Akanda was 2024 -726.52 % . It decreases by 324.71% lower compared to the previous year.

The Akanda FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2020
-86,886.76 USD
Jan 1, 2021
-17,217.87 USD
Jan 1, 2022
-449.69 USD
Jan 1, 2023
-69.54 USD
Jan 1, 2024
-726.52 USD
Jan 1, 2025
-3,085.58 USD
The Akanda FCF Margin history
YEARFCF MarginYoY
-3,085.58 %+324.71%
-726.52 %+944.76%
-69.54 %-84.54%
-449.69 %-97.39%
-17,217.87 %-80.18%
-86,886.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Free Cash Flow Margin of Akanda is -3,085.58 % in 2025.

Free Cash Flow Margin of Akanda changed from -726.52 % to -3,085.58 %, representing a 324.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Akanda since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Akanda with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Akanda

All Key Metrics — Akanda